Risk-Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach.
Article Details
- CitationCopy to clipboard
Ezuruike U, Humphries H, Dickins M, Neuhoff S, Gardner I, Rowland Yeo K
Risk-Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach.
Clin Pharmacol Ther. 2018 Dec;104(6):1229-1239. doi: 10.1002/cpt.1085. Epub 2018 Apr 27.
- PubMed ID
- 29637542 [ View in PubMed]
- Abstract
Current formulations of combined oral contraceptives (COC) containing ethinylestradiol (EE) have
DrugBank Data that Cites this Article
- Drugs
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Ethinylestradiol Cytochrome P450 1A2 Protein Humans UnknownSubstrateDetails Ethinylestradiol Cytochrome P450 2C8 Protein Humans UnknownSubstrateInhibitorDetails Ethinylestradiol Cytochrome P450 2C9 Protein Humans UnknownSubstrateDetails Ethinylestradiol Cytochrome P450 3A4 Protein Humans UnknownSubstrateDetails Ethinylestradiol UDP-glucuronosyltransferase 1-1 Protein Humans NoSubstrateInducerDetails - Drug Reactions
Reaction Details Details Details Details Details Details